Why Is ACADIA PHARMACEUTICA (ACAD) Stock Down Today?

Acadia Pharmaceuticals shares fell 22.28% to close at $16.50. The primary driver was the company’s comment on the Federal Circuit oral argument in its NUPLAZID formulation patent appeal. This legal development triggered a sharp sell-off in the stock.

What Happened

Acadia Pharmaceuticals provided an update regarding the oral argument in the Federal Circuit appeal concerning its NUPLAZID formulation patent. The company also announced it will present remlifanserin data at the 2026 Clinical Trials on Alzheimer's Disease Conference. Additionally, the firm published its third-quarter 2026 earnings call presentation. These disclosures occurred within the last 36 hours. The stock had been on a modest upward trend, rising 4.5% over the previous eight sessions from $20.32 to $21.23.

What The Data Shows

The session opened at $21.35, a 0.6% gap up from the prior close. The stock reached a session high of $21.66 at 10:35 AM ET before sliding to a low of $15.10 at 4:15 PM ET. Volume reached 10.8 million shares, which is 5.9 times the three-month daily average. The 52-week tape recorded four fresh 52-week highs and 27 fresh 52-week lows on November 9, 2026. Fundamentals show a market cap of $3.7 billion, a P/E of 10.1, and revenue growth of 14.8% on a trailing twelve-month basis. The net margin stands at 30.1% with a beta of 0.89. The 52-week range is $18.39 to $30.96. Recent analyst activity included Deutsche Bank adjusting its price target to $30, Canaccord Genuity raising its target to $38, and RBC Capital Markets raising its target. Mark C. Schneyer, EVP and CFO, sold shares on October 30, 2026.

What To Watch

Investors will monitor the company's upcoming presentation of remlifanserin data at the 2026 CTAD Conference. The outcome of the Federal Circuit appeal will also remain a key focus for the stock's near-term direction.